Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300

Schizophrenia Research

Volumn 101, Issue 1-3, 2008, Pages 320-330

  Higuchi, Yuko ^a   Sumiyoshi, Tomiki ^a,b   Kawasaki, Yasuhiro ^a,b   Matsui, Mie ^a,b   Arai, Hirofumi ^a,b   Kurachi, Masayoshi ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Atypical antipsychotic drugs; Cognition; Event related potentials; LORETA; Negative symptoms; Quality of Life; Schizophrenia; Superior temporal gyrus

Indexed keywords

OLANZAPINE;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; COGNITION; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GENDER; HEMISPHERE; HUMAN; LEARNING; LOW RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; TASK PERFORMANCE; VERBAL MEMORY; VOLUNTEER;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN MAPPING; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REGRESSION ANALYSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; VERBAL LEARNING;

EID: 42749090978     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.01.020     Document Type: Article

References (63)

1. Alexander J.E., Bauer L.O., Kuperman S., Morzorati S., O'Connor S.J., Rohrbaugh J., Porjesz B., Begleiter H., and Polich J. Hemispheric differences for P300 amplitude from an auditory oddball task. Int. J. Psychophysiol. 21 (1996) 189-196
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
3. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa City
4. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) (1983), University of Iowa, Iowa City
5. Bilker W.B., Brensinger C., Kurtz M.M., Kohler C., Gur R.C., Siegel S.J., and Gur R.E. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology 28 (2003) 773-777
6. Bruder G.E., Tenke C.E., Towey J.P., Leite P., Fong R., Stewart J.E., McGrath P.J., and Quitkin F.M. Brain ERPs of depressed patients to complex tones in an oddball task: relation of reduced P3 asymmetry to physical anhedonia. Psychophysiology 35 (1998) 54-63
7. Bruder G., Kayser J., Tenke C., Amador X., Friedman M., Sharif Z., and Gorman J. Left temporal lobe dysfunction in schizophrenia: event-related potential and behavioral evidence from phonetic and tonal dichotic listening tasks. Arch. Gen. Psychiatry 56 (1999) 267-276
8. 1A receptor agonism. Brain Res. 1023 (2004) 54-63
9. Crow T.J. Schizophrenia as failure of hemispheric dominance for language. Trends Neurosci. 20 (1997) 339-343
10. Fabiani M., Gratton G., and Karis D. Definition, identification, and reliability of measurement of P300 component of the event related potentials. Advances in Psychophysiology vol. II (1987) 1-78
11. Farde L., Ito H., Swahn C.G., Pike V.W., and Halldin C. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J. Nucl. Med. 39 (1998) 1965-1971
12. Gallinat J., Mulert C., Bajbouj M., Herrmann W.M., Schunter J., Senkowski D., Moukhtieva R., Kronfeldt D., and Winterer G. Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage 17 (2002) 110-127
13. Gonul A.S., Suer C., Coburn K., Ozesmi C., Oguz A., and Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 173-177
14. Heinrichs D.W., Hanlon T.E., and Carpenter W.T.J. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 10 (1984) 388-398
15. Holmes A.P., Blair R.C., Watson J.D., and Ford I. Nonparametric analysis of statistic images from functional mapping experiments. J. Cereb. Blood. Flow Metab. 16 (1996) 7-22
16. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., and Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13432-13437
17. Huang M., Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Res. 1099 (2006) 44-55
18. Jeon Y.W., and Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40 (2003) 684-701
19. Kawasaki Y., Maeda Y., Higashima M., Nagasawa T., Koshino Y., Suzuki M., and Ide Y. Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia. Schizophr. Res. 26 (1997) 107-115
20. Kawasaki Y., Sumiyoshi T., Higuchi Y., Ito T., Takeuchi M., and Kurachi M. Voxel-based analysis of P300 electrophysiological topography associated with positive and negative symptoms of schizophrenia. Schizophr. Res. 94 (2007) 164-171
21. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Lewine R.R., Yurgelun-Todd D.A., Gur R.C., Tohen M., Tollefson G.D., Sanger T.M., and Lieberman J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161 (2004) 985-995
22. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., Sanger T.M., and Lieberman J.A. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry. 59 (2006) 97-105
23. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., and Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 81 (2006) 1-15
24. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., and Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64 (2007) 633-647
25. Korostenskaja M., Dapsys K., Siurkute A., Maciulis V., Ruksenas O., and Kahkonen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 543-548
26. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
27. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., and Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005) 361-370
28. Matsui M., Sumiyoshi T., Kato K., and Masayoshi K. Development of alternate forms of Japanese Verbal Learning Test. Seishin Igaku (Clinical Psychiatry) 49 1 (2007) 31-34
29. Matsuoka K., Uno M., Kasai K., Koyama K., and Kim Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin. Neurosci. 60 (2006) 332-339
30. Meltzer H.Y., and Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry. 53 (2003) 265-267 author reply 267-8
31. Meltzer H.Y., Matsubara S., and Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25 (1989) 390-392
32. Meltzer H.Y., Park S., and Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Nat. Acad. Sci. 96 (1999) 13591-13593
33. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
34. Molina V., Munoz F., Martin-Loeches M., Casado P., Hinojosa J.A., and Iglesias A. Long-term olanzapine treatment and p300 parameters in schizophrenia. Neuropsychobiology 50 (2004) 182-188
35. Mori K., Nagao M., Yamashita H., Morinobu S., and Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 659-665
36. Mulert C., Pogarell O., Juckel G., Rujescu D., Giegling I., Rupp D., Mavrogiorgou P., Bussfeld P., Gallinat J., Moller H.J., and Hegerl U. The neural basis of the P300 potential. Focus on the time-course of the underlying cortical generators. Eur. Arch. Psychiatry Clin. Neurosci. 254 (2004) 190-198
37. Nagasawa T., Kamiya T., Kawasaki Y., Higashima M., Urata K., Sakai N., and Koshino Y. The relationship between auditory ERP and neuropsychological assessments in schizophrenia. Int. J. Psychophysiol. 34 (1999) 267-274
38. Nieman D.H., Koelman J.H., Linszen D.H., Bour L.J., Dingemans P.M., and Ongerboer de Visser B.W. Clinical and neuropsychological correlates of the P300 in schizophrenia. Schizophr. Res. 55 (2002) 105-113
39. Niznikiewicz M.A., Patel J.K., McCarley R., Sutton J., Chau D.T., Wojcik J., and Green A.I. Clozapine action on auditory P3 response in schizophrenia. Schizophr. Res. 76 (2005) 119-121
40. Nohara S., Suzuki M., Kurachi M., Yamashita I., Matsui M., Seto H., and Saitoh O. Neural correlates of memory organization deficits in schizophrenia: a single photon emission computed tomography study with 99m-Tc-ethyl-cysteinate dimmer during a verbal learning task. Schizophr. Res. 42 (2000) 209-222
41. Ogawa T. Table of frequency in the recall of words belonging to 52 categories. J. Lit. Assoc. Kwansei Gakuin Univ. 22 (1972) 1-60
42. Pae J.S., Kwon J.S., Youn T., Park H.J., Kim M.S., Lee B., and Park K.S. LORETA imaging of P300 in schizophrenia with individual MRI and 128-channel EEG. Neuroimage 20 (2003) 1552-1560
43. Pascual-Marqui R.D., Lehmann D., Koenig T., Kochi K., Merlo M.C., Hell D., and Koukkou M. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. Psychiatry Res. 90 (1999) 169-179
44. Phillips G.A., Van Brunt D.L., Roychowdhury S.M., Xu W., and Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J. Clin. Psychiatry 67 (2006) 1397-1403
45. Renoult L., Prevost M., Brodeur M., Lionnet C., Joober R., Malla A., and Debruille J.B. P300 asymmetry and positive symptom severity: a study in the early stage of a first episode of psychosis. Schizophr. Res. 93 (2007) 366-373
46. Revicki D., Genduso L., Hamilton S., Ganoczy D., and Beasley Jr. C. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual. Life Res. 8 (1999) 417-426
47. Shapleske J., Rossell S.L., Woodruff P.W., and David A.S. The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Brain Res. Brain Res. Rev. 29 (1999) 26-49
48. Stockmeier C.A., DiCarlo J.J., Zhang Y., Thompson P., and Meltzer H.Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 266 (1993) 1374-1384
49. Strik W.K., Dierks T., Franzek E., Stober G., and Maurer K. P300 asymmetries in schizophrenia revisited with reference-independent methods. Psychiatry Res. 55 (1994) 153-166
50. Sumiyoshi T., and Meltzer H. Pharmacological strategy for enhancement of social function and quality of life in patients with schizophrenia: considerations of the effect of melperone, and atypical antipsychotic drug on cognitive function. Seishin Igaku (Clinical Psychiatry) 4 12 (2003) 1279-1284
51. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Thompson P.A., and Meltzer H.Y. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate of subjects with schizophrenia or major depression. Brain Res. 681 (1995) 109-116
52. Sumiyoshi T., Jayathilake K., and Meltzer H.Y. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr. Res. 59 (2003) 7-16
53. Sumiyoshi C., Sumiyoshi T., Roy A., Jayathilake K., and Meltzer H.Y. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analysis of category fluency performance in schizophrenia. Int. J. Neuropsychopharmacol. 6 (2006) 677-683
54. Sumiyoshi T., Higuchi Y., Kawasaki Y., Matsui M., Kato K., Yuuki H., Arai H., and Kurachi M. Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 1299-1303
55. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., and Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res. 157 (2008) 87-93
56. Suzuki H., Omoto M., Inoue Y., Sekiguchi G., Akimoto T., Gen K., Morokawa Y., and Aoba A. Comparison of clinical symptoms and cognitive function before and after olanzapine switching in schizophrenia patients. Jpn. J. Clin. Psychopharmacol. 9 (2006) 881-891
57. Talairach J., and Tournoux P. Co-Planar Stereotaxic Atlas of Human Brain (1988), Thieme, Stuttgart
58. Towle V.L., Bolanos J., Suarez D., Tan K., Grzeszczuk R., Levin D.N., Cakmur R., Frank S.A., and Spire J.P. The spatial location of EEG electrodes: locating the best-fitting sphere relative to cortical anatomy. Electroencephalogr. Clin. Neurophysiol. 86 (1993) 1-6
59. Umbricht D., Javitt D., Novak G., Bates J., Pollack S., Lieberman J., and Kane J. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol. Psychiatry 44 (1998) 716-725
60. Wechsler D. WAIS-R Manual. Wechsler Adult Intelligence Scale-Revised (1981), Psychological Corp., New York, NY
61. Winterer G., Mulert C., Mientus S., Gallinat J., Schlattmann P., Dorn H., and Herrmann W.M. P300 and LORETA: comparison of normal subjects and schizophrenic patients. Brain Topogr. 13 (2001) 299-313
62. Woodward N.D. A meta-analysis of neuropsychological change with second generation antipsychotics in schizophrenia. 24th CINP Congress (2006), Chicago, USA
63. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472